| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3974560b90f4d5a2b745fb2d66466ac0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_57da2a8599067693144a48dfead25609
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9a067afdc7ccdb0027ef5e0423963ecf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f87ffb1f496dcfc1f2d3285f3942906
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_147dc860264a3641d709bd8b082651d4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
| filingDate |
2008-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_237d6952aed6547c45fc577be689b302
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5529294c1e3a145b31b24d802c20dd3f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32545469a1077b073edf5ebc011bebd7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67921f31e804897831e7fd81124095d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1a6ada76d43ead16bca21835b982b45 |
| publicationDate |
2009-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009063367-A1 |
| titleOfInvention |
Dosage forms comprising celecoxib providing both rapid and sustained pain relief |
| abstract |
A pharmaceutical dosage form comprising celecoxib and a pharmaceutically acceptable carrier, the dosage form when initially administered to at least 12 human patients in the fasted state in a crossover study providing: (a) a mean blood plasma concentration of celecoxib within 0.5 hour after administration (C0.5) of at least about 0.9 ng/ml per mg of celecoxib dosed; (b) a mean blood plasma concentration of celecoxib 12 hours after administration (Ci2) of at least about 0.6 ng/ml per mg of celecoxib dosed; (c) a mean area under the blood plasma concentration versus time curve for the 12 hour period following administration (AUC12) of at least 19 ng- hr/mL per mg of celecoxib dosed; and (d) a mean maximum blood plasma concentration (Cmax) of celecoxib of less than about 4.9 ng/ml per mg of celecoxib dosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010122482-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4062941-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114340650-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009118167-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010101485-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022040141-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017186889-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IT-RM20090180-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108524527-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108524527-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105168137-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3448435-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010150144-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021042276-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010134025-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010134025-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010150144-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011050944-A1 |
| priorityDate |
2007-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |